Breaking News, Collaborations & Alliances

PeptiDream Expands Peptide Discovery Collaboration with Novartis

Will use its Peptide Discovery Platform System technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

PeptiDream Inc., a Japan-based biopharmaceutical company, is expanding its peptide discovery collaboration with Swiss-based Novartis Pharma AG.
 
Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify and optimize novel macrocyclic peptides against targets selected by Novartis, for potential conjugation to radionuclides or other applications for both therapeutic and diagnostic purposes.
 
This new agreement expands upon the peptide-drug conjugate (PDC) collaboration announced in 2019, and further highlights the two companies’ long-standing discovery efforts, originally initiated in 2010, and extended multiple times.
 
Under the terms of the agreement, PeptiDream will receive an upfront payment of $180 million from Novartis. In addition, PeptiDream is eligible to receive up to $2.71 billion in payments based on the achievement of specified development, regulatory and commercial milestones, plus tiered royalties on net sales of any such products arising from the collaboration.
 
“We are delighted to further expand our long-standing macrocyclic peptide discovery collaboration with Novartis, adding additional peptide RLT and other programs to our strong partnership,” said Patrick C. Reid, Ph.D., CEO of PeptiDream. “As macrocyclic peptides continue to be the ideal vectors for the targeted deliver of a variety of therapeutic payloads, PeptiDream continues to build an extensive pipeline of partnered as well as internal peptide-conjugate programs.”
 
“We are enthusiastic about the progress we’ve made with PeptiDream through our long-standing research collaboration and look forward to continuing our work together as we strive to create impactful new therapies for patients,” said Shiva Malek, Global Head of Oncology Research at Novartis. “Our expanded partnership reflects our shared commitment to pioneering science that broadens the scope of transformative therapeutic approaches such as RLT.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters